We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Sam7.0
SAMe Research
Mixed evidence
86 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most SAMe studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1984–2026 with a typical study size of 676 participants.
Based on 86 studies · 12 meta-analyses · 60 RCTs · 3,367 total participants
Confidence
High confidence
What the studies found
1helped1unclear· 84 more without graded effect data
By outcome
Depression & moodSignificant improvement in depressive symptoms · 2-6 weeks
Mostly mechanism / observational74 studies
Therapeutic & clinical
Mostly mechanism / observational26 studies
Liver health
Mostly mechanism / observational22 studies
Women's health
Mostly mechanism / observational14 studies
Joint pain & arthritisComparable to NSAIDs for osteoarthritis pain in clinical trials · 4-8 weeks
Mostly mechanism / observational11 studies
Cognitive function
Mostly mechanism / observational3 studies
Neuroprotection & brain aging
Mostly mechanism / observational3 studies
Energy & fatigue
Too few graded studies2 studies
Heart & blood pressure
Too few graded studies1 study
Safety profile
Too few graded studies1 study
By the numbers
Pulled from 9 studies with measurable effects
People studied
3,367
typical study: 676 people
Strongest designs
72
12 pooled, 60 randomised
Showed benefit
50%
1/2 studies
How long studies ran
1–3 months
1
Populations Studied
Patients with mild depression1
Patients with depression1
Males with arousal and erectile dysfunction1
Mammals during starvation1
Steady research
16 studies in the last 5 years · Latest meta-analysis: 2025
198420052026
1Response ratesMeta-Analysisn=1,049 · large study2025
In plain English: This review demonstrates that certain supplements, such as eicosapentaenoic acids and Rhodiola rosea, are therapeutic options for mild depression.
Urata M et al. · Neuropsychopharmacology reports (2025)
No clear effect
← WorseNo effectBetter →
A meta-analysis found no significant difference in response rates between the two treatments (risk ratio [RR] = 0.96, 95% CI: 0.78-1.18) or dropout rates (RR = 1.08, 95% CI: 0.62-1.88).
Eicosapentaenoic acid and Rhodiola rosea demonstrated significant improvements in depressive symptoms compared to placebo.
Conversely, S-adenosylmethionine did not produce significant improvements relative to placebo.
In plain English: Moderate-certainty evidence suggests that SAMe monotherapy may offer a moderate therapeutic benefit in alleviating depressive symptoms.
Limveeraprajak N et al. · Progress in neuro-psychopharmacology & biological psychiatry (2024)
Moderate-certainty evidence suggests that SAMe monotherapy may offer a moderate therapeutic benefit in alleviating depressive symptoms.
Considering its favorable acceptability profile, SAMe monotherapy should be considered as a treatment option for patients with depression.
However, uncertainties regarding its efficacy as an adjunct to AD and its comparative efficacy with ADs remain unresolved.
The results of SAMe versus placebo as a monotherapy, SAMe versus imipramine or escitalopram as a monotherapy, and SAMe versus placebo as an adjunctive therapy, showed no significant difference in depression with SAMe compared to the comparison treatment.
Conclusions SAMe may provide relief of depression symptoms similar to imipramine or escitalopram.
However, the results of the comparisons should be interpreted with caution due to the small number of studies and the large range of SAMe doses that were used in the included trials.
In plain English: Appropriate levels of these micronutrients should then be monitored at all stages of development for a healthier brain.
Bekdash RA · International journal of molecular sciences (2023)
Studies in human and animal models have indicated the importance of the optimal levels of methyl donors on brain health and behavior across the lifespan.
Imbalances in the levels of these micronutrients during critical periods of brain development have been linked to epigenetic alterations in the expression of genes that regulate normal brain function.
We present studies that support the link between imbalances in the levels of methyl donors, epigenetic alterations, and stress-related disorders.
In plain English: The food supplement showed a significant decrease of PHQ-9 and HAM-D scores resulting in reduced SD and MDD symptoms as compared to placebo.
Ullah H et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022)
The food supplement showed a significant decrease of PHQ-9 and HAM-D scores resulting in reduced SD and MDD symptoms as compared to placebo.